Eight important updates for National Sickle Cell Awareness Month
Click Here to Manage Email Alerts
September is National Sickle Cell Awareness Month.
The congressional designation is intended to focus attention on the need for improved treatments and additional research for the condition, which affects an estimated 100,000 people in the United States.
In conjunction with this observation, Healio and HemOnc Today provide the following updates in sickle cell disease.
1. Researchers at UPMC Children’s Hospital of Pittsburgh found a novel reduced-intensity conditioning regimen paired with umbilical cord blood appeared safe and effective for treating several genetic noncancerous disorders, including sickle cell disease. Read more.
2. The FDA granted rare pediatric disease designation to EDIT-301 (Editas Medicine), an investigational autologous cell therapy for the treatment of sickle cell disease. Read more.
3. Receiving medical marijuana appeared associated with reduced hospital admission rates among patients with sickle cell disease. Read more.
4. Vaporized cannabis did not significantly reduce chronic pain and most associated symptoms compared with placebo among adults with sickle cell disease. Read more.
5. Negative perceptions of care in the ED setting appeared to be a barrier to seeking care among adolescents and adults with sickle cell disease. Read more.
6. Escalated dosing of hydroxyurea had greater clinical efficacy than fixed dosing of the drug for children with sickle cell disease in sub-Saharan Africa. Read more.
7. LentiGlobin (bluebird bio) gene therapy led to reductions in sickle cell disease-related complications and hemolysis. Read more.
8. The Sickle Cell Disease Association of America issued an updated provider advisory for the acute and chronic management of patients with sickle cell disease during the COVID-19 pandemic. Read more.
Collapse
Healio coverage
Read more about
Click Here to Manage Email Alerts